Amryt Pharma plc

NasdaqGS:AMYT Stock Report

Market Cap: US$940.7m

Amryt Pharma Future Growth

Future criteria checks 5/6

Amryt Pharma is forecast to grow earnings and revenue by 53.9% and 26.3% per annum respectively while EPS is expected to grow by 50.8% per annum.

Key information

53.9%

Earnings growth rate

50.8%

EPS growth rate

Pharmaceuticals earnings growth24.0%
Revenue growth rate26.3%
Future return on equityn/a
Analyst coverage

Low

Last updated12 Apr 2023

Recent future growth updates

Recent updates

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Oct 18

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Sep 16

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Sep 08

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Jul 14

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

Jun 23

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Dec 09

Chiasma surges on merger agreement with Amryt

May 05

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Feb 04

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Dec 23

Amryt Group's Lojuxta receives marketing approval in Brazil

Dec 09

Earnings and Revenue Growth Forecasts

NasdaqGS:AMYT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025595153N/AN/A1
12/31/2024428141N/AN/A2
12/31/2023325-359N/A4
12/31/2022266-6434N/A4
9/30/2022244-1107108N/A
6/30/20222393-32-30N/A
3/31/2022233345N/A
12/31/202122311416N/A
9/30/2021210-88-89-86N/A
6/30/2021203-814650N/A
3/31/2021186-922123N/A
12/31/2020183-1052427N/A
9/30/2020180-8756N/A
6/30/2020140-92-18-17N/A
3/31/202098-87-26-26N/A
12/31/201958-63-38-37N/A
12/31/201817-30-16-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMYT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: AMYT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AMYT is expected to become profitable in the next 3 years.

Revenue vs Market: AMYT's revenue (26.3% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: AMYT's revenue (26.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AMYT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/14 14:05
End of Day Share Price 2023/04/11 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amryt Pharma plc is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michelle GilsonCanaccord Genuity
Brandon FolkesCantor Fitzgerald & Co.
Andrew YoungDavy